Predictive Oncology secures $10M in partnership with Yorkville Advisors to advance AI-driven drug discovery and repurposing initiatives.

Predictive Oncology has entered a $10M standby equity purchase agreement with Yorkville Advisors to advance AI-driven drug discovery and repurposing. The partnership will provide Predictive Oncology with a flexible source of funding to progress its ongoing initiatives and business development opportunities with leading biopharmaceutical companies. Predictive Oncology will control the timing and amount of all sales of common stock, with no minimum commitments or penalties.

Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, has entered into a $10 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global's investment fund. This agreement provides Predictive Oncology with flexible funding access to advance its AI-driven drug discovery and repurposing initiatives.

Under the SEPA terms, Predictive Oncology maintains full control over the timing and amount of stock sales, with no warrants, derivatives, or minimum commitments required. The funding will support ongoing drug discovery, biomarker research, and business development opportunities with biopharmaceutical companies through its AI and machine learning capabilities.

The SEPA allows Predictive Oncology to sell up to $10 million worth of common stock to Yorkville, at the company's sole discretion. There are no minimum commitments or penalties associated with the agreement, providing Predictive Oncology with a flexible source of funding to progress its initiatives without any restrictions on its operating activities.

This agreement is expected to enhance Predictive Oncology's ability to leverage its novel AI platform, PEDAL, which predicts with 92% accuracy if a tumor sample will respond to a certain drug compound. The company's vast biobank of over 150,000 assay-capable human tumor samples further complements its AI-based drug discovery solutions.

Predictive Oncology is headquartered in Pittsburgh, PA, and is on the cutting edge of using artificial intelligence and machine learning to expedite early drug discovery and enable drug development for cancer patients worldwide.

References:
[1] https://www.stocktitan.net/news/POAI/predictive-oncology-announces-10m-share-purchase-agreement-in-3u0x90li84o7.html